Experienced in Budd-Chiari Syndrome

Dr. Andrea J. Bullock

Hematology
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
330 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Experienced in Budd-Chiari Syndrome
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
330 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrea Bullock is a Hematologist in Boston, Massachusetts. Dr. Bullock is rated as an Experienced provider by MediFind in the treatment of Budd-Chiari Syndrome. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Gallbladder Adenocarcinoma, Non-Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gamma Knife Radiosurgery. Dr. Bullock is currently accepting new patients.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Budd-Chiari Syndrome.

Specialties
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Hospital Plymouth
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

HARVARD MEDICAL FACULTY PHYS AT BETH ISRAEL DEACONESS MED CTR INC
330 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug
Study Phase: Phase 1
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

66 Total Publications

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Journal: JCO precision oncology
Published: September 02, 2025
Similar Doctors
Advanced in Budd-Chiari Syndrome
Dr. Rasmia A. Ahmed
Hematology Oncology | Hematology | Oncology
Advanced in Budd-Chiari Syndrome
Dr. Rasmia A. Ahmed
Hematology Oncology | Hematology | Oncology

Charles River Medical Associates, PC

571 Union Ave, Suite 202, 
Framingham, MA 
 (16.8 miles away)
508-665-6261
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rasmia Ahmed is a Hematologist Oncology specialist and a Hematologist in Framingham, Massachusetts. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Budd-Chiari Syndrome. Her top areas of expertise are Anemia, Myelodysplastic Syndrome (MDS), Thrombocytopenia, and Shwartzman Phenomenon. Dr. Ahmed is currently accepting new patients.

Experienced in Budd-Chiari Syndrome
Dr. David Kuter
Hematology
Experienced in Budd-Chiari Syndrome
Dr. David Kuter
Hematology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kuter is a Hematologist in Boston, Massachusetts. Dr. Kuter is rated as an Elite provider by MediFind in the treatment of Budd-Chiari Syndrome. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy.

Experienced in Budd-Chiari Syndrome
Dr. David B. Smith
Hematology | Oncology
Experienced in Budd-Chiari Syndrome
Dr. David B. Smith
Hematology | Oncology
55 Fruit St, Yaw 7, 
Boston, MA 
 (2.5 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Smith is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Budd-Chiari Syndrome. His top areas of expertise are Essential Thrombocythemia, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Autoimmune Hemolytic Anemia. Dr. Smith is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bullock's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile